Volume | 13,587 |
|
|||||
News | - | ||||||
Day High | 2.12 | Low High |
|||||
Day Low | 2.02 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aditxt Inc | ADTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.02 | 2.02 | 2.12 | 2.10 | 2.04 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
149 | 13,587 | $ 2.08 | $ 28,309 | - | 1.95 - 68.08 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:30:34 | 76 | $ 2.01 | USD |
Aditxt Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.5M | 1.67M | - | 934k | -27.65M | -16.60 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aditxt News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.38 | 2.48 | 1.95 | 2.22 | 37,170 | -0.28 | -11.76% |
1 Month | 3.2177 | 3.27 | 1.95 | 2.54 | 51,371 | -1.12 | -34.74% |
3 Months | 3.86 | 5.09 | 1.95 | 3.35 | 323,500 | -1.76 | -45.60% |
6 Months | 5.90 | 9.50 | 1.95 | 5.40 | 838,722 | -3.80 | -64.41% |
1 Year | 26.032 | 68.08 | 1.95 | 9.17 | 556,253 | -23.93 | -91.93% |
3 Years | 113.60 | 1,139.60 | 1.95 | 48.80 | 2,266,317 | -111.50 | -98.15% |
5 Years | 211.20 | 1,139.60 | 1.95 | 72.65 | 2,192,071 | -209.10 | -99.01% |
Aditxt Description
Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues. |